Navigation Links
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
Date:12/7/2009

PINE BROOK, N.J., Dec. 7 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced today that recent animal efficacy and human safety data from the Company's Anthim® anthrax anti-toxin program were presented at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day conference, December 4, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

In a podium presentation entitled "Advanced Development of Anthim® (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalational Anthrax: results of recent safety and efficacy studies," Dr. Leslie Casey, Vice President of Research, presented data from rabbit and primate treatment studies as well as clinical safety studies highlighting the therapeutic potential for Anthim in the treatment of anthrax disease. Using an established non-human primate treatment model, up to 79% of animals treated with a single, intravenous dose of Anthim at the onset of symptoms survived a lethal inhalational challenge with anthrax spores. All animals in this study were bacteremic at time of Anthim treatment.

The Company also reported the results of a previously conducted rabbit treatment study. A single dose of Anthim provided up to 94% survival when administered to rabbits after symptoms of disease were present. The results of these two studies are consistent with previously conducted rabbit and primate studies using Anthim and continue to show the dramatic increase in survival that Anthim can provide.

In a separate dose-escalating human clinical safety study, preliminary results show that Anthim continues to be safe and well-tolerated at doses at or above the anticipated efficacious dose in humans.

Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the continued success of our Anthim program as we move into the final stages of drug development. Anthim consistently provides significant survival benefit in the treatment of anthrax infection and is safe and well-tolerated. Our drug has the potential to deliver considerable therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

This project has been supported with federal funds from BARDA, Department of Health and Human Services (HHS), in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

Anthim Background

Anthim has been extensively studied in multiple models of anthrax infection and has consistently prevented death in 70 - 100% of animals treated with a single dose of drug. Anthim shows excellent potential as an effective therapeutic for treatment of people infected or exposed to anthrax spores.

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. To date, Elusys has been awarded a total of $34 million in government funding for advanced development of Anthim. Funding has been received from the NIAID, BARDA, HHS, and the Department of Defense.

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

SOURCE Elusys Therapeutics, Inc.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
2. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
3. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
4. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
9. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
10. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
11. Dr. Julian Henley MD Presents BioMatrix Lift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
(Date:7/14/2017)... 2017 Endo International plc (NASDAQ: ENDP ) ... 2017.  Members of its senior management team will host a conference ... a.m. ET. The dial-in number to access the ... 509-7598, and the passcode is 45397076. Please dial in 10 minutes ... A replay of the call will be available from ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire ... site and threatened numerous homes and businesses nearby, causing some 700 individuals to ... Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the report ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care product, ... of the leading causes of long term skin conditions, including cancer. In ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 ... MD. This year's theme focuses on the new ISO/IEC 17025 standards. This marks ... integrity in testing and calibration will be changed. , As an exhibitor, ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created in ... 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable won ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... Medicine Clinical Vitiligo Hospital" was set up, and the awarding ceremony was held ... Chinese medicine, the head of the army's health system, and national Chinese medicine ...
Breaking Medicine News(10 mins):